United States Air Force
Also known as: 11 MDG | 375th Medical Group, Scott Air Force Base | Air Force | Air Force Research Laboratory | Air Force Specialized Hospital | David Grant Medical Center | David Grant U.S. Air Force Medical Center | Eglin AFB Hospital | Eglin AFB Regional Hospital | Eglin AFB, United States Air Force | Jennifer Loomis | Keesler Air Force Base Medical Center | Matthew Snyder | Mike O'Callaghan Federal Hospital | Mike O'Callaghan Federal Hospital/Nellis Air Force Base | Mike O'Callaghan Federal Medical Center | Mike O'Callaghan Military Hospital | Mike O'Callaghan Military Medical Center | Nellis AF | Seth Leavitt | Travis Callahan | United States Air Force | United States Air Force Research Laboratory | United States Air Force School of Aerospace Medicine | USAF David Grant Medical Center | US Air Force | U.S. Air Force Office of the Surgeon General | Wilford Hall Medical Center | Wilford Hall Medical Center, Lackland AFB, San Antonio, TX
Highest phase reached
Phase 4
First clinical trial
Dec 1, 1997Last known activity
May 30, 2025
Timeline
1900s
- Aug 1, 1907
United States Air Force— Founded
Drugs by trial phase (49 distinct, 45 trials)
Phase 4 (7 own, 0 via acquisition)
Phase 3 (14 own, 0 via acquisition)
Phase 2 (5 own, 0 via acquisition)
Other trials (23 own, 0 via acquisition)
Indications
Studied for
- Abdomen, Acute
- Abscess
- Acute Pain
- Anovulation
- Back Pain
- Carcinoma
- Carcinoma, Squamous Cell
- Chronic Pain
- Cicatrix
- Compartment Syndromes
- Depression
- Depressive Disorder
- Dyspepsia
- Emergencies
- Flank Pain
- Fractures, Bone
- Gout
- Headache
- Hyperandrogenism
- Infertility
- Influenza, Human
- Low Back Pain
- Polycystic Ovary Syndrome
- Postoperative Pain
- Rib Fractures
- Sepsis
- Shock
- Shock, Septic
- Squamous Cell Carcinoma of Head and Neck
- Syndrome
- Systemic Inflammatory Response Syndrome
- Thromboembolism
- Toxemia
- Venous Thromboembolism
- Wounds and Injuries
Recent trials (50)
- NCT06955923Lead sponsorPhase 2May 30, 2025
- NCT05586646Study directorN/AApr 1, 2022
- NCT05849558OfficialPhase 4Feb 22, 2022
- NCT05849558Overall official - principal investigatorPhase 4Feb 22, 2022
- NCT04240483Sponsor investigatorN/AJul 27, 2020
- NCT04240483OfficialN/AJul 27, 2020
- NCT04240483Lead sponsorN/AJul 27, 2020
- NCT04343677Study chairPhase 2Apr 30, 2020
- NCT04343677Overall official - principal investigatorPhase 2Apr 30, 2020
- NCT04508946Overall official - principal investigatorPhase 3Aug 1, 2019
- NCT03843671CollaboratorPhase 2Jul 1, 2019
- NCT03936309Lead sponsorPhase 2May 31, 2019
- NCT03936309CollaboratorPhase 2May 31, 2019
- NCT03933436Sponsor investigatorN/AMay 31, 2019
- NCT03936309Sponsor investigatorPhase 2May 31, 2019
Details
- Founded
- Washington, DC, US Aug 1, 1907
- Last known activity
- May 30, 2025